Generative AI helps Hong Kong’s Insilico Medicine design potential new IBD drug

Quick Summary:

Using AI, Insilico took only 12 months from initiating the project to nominating the molecule for preclinical trials, instead of several years.

The company also used its generative biologics AI platform, PandaOmics, to identify its IBD therapeutic target, which its new AI-designed molecule would specifically inhibit to achieve therapeutic effect.

Existing drugs for the long-term condition IBD, such as Crohn’s disease and ulcerative colitis, a re limited a s they present risks including cardiovascular and tumorigenic side effects, according to Insilico’s paper.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Xinmei Shen

Category: Technology

Markets: Hong Kong

Topics: Platform According Molecule Disease Paper Drug Insilico Generative Medicine Able Effects

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-12-11 @ 18:00:17 (6 days ago)

News Timezone: GMT +8:00

News Source URL: scmp.com

Language: English

Article Length: 213 words

Reading Time: 2 minutes read

Sentences: 5 lines

Sentence Length: 43 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © SCMP

News ID: 24495638

View Article Analysis

About SCMP

Main Topics: Technology

Official Website: scmp.com

Update Frequency: 1 posts per day

Year Established: 1903

Headquarters: Hong Kong

News Last Updated: 12 hours ago

Coverage Areas: Hong Kong

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #41

Publisher Details

Frequently Asked Questions